🇺🇸 FDA
Patent

US 6207170

Patient-specific white blood cell malignancy vaccine from membrane-proteoliposomes

expired A61KA61K2039/55522A61K2039/55527

Quick answer

US patent 6207170 (Patient-specific white blood cell malignancy vaccine from membrane-proteoliposomes) held by Biomira USA Inc. expires Mon Mar 22 2021 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.

Key facts

Applicant
Biomira USA Inc.
Grant date
Tue Mar 27 2001 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 22 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K2039/55522, A61K2039/55527, A61K2039/55533, A61K2039/5555